Objectives-We aimed to investigate the effect of ultrasound (US)-guided injections of the rhomboid major (deep) and trapezius (superficial) muscles on pain, disability, and quality of life in patients with myofascial pain syndrome.
M
yofascial pain syndrome is a regional pain syndrome accompanied by sensory, motor, and autonomic symptoms. 1 It is characterized by active myofascial trigger points in the form of focal hyperirritable nodules that are palpable in the tight bands of a muscle. 2, 3 Myofascial trigger points are most frequently detected in the upper trapezius, levator scapula, and axial postural muscles such as the rhomboid major. 4 Oral medication, ischemic compression, massage, local anesthetic (wet) injections, superficial and deep dry needling, botulinum toxin A injection, and several physical therapy modalities are used for treatment of myofascial pain syndrome. 5, 6 The rhomboid major muscle originates from the spinous processes of the T2 through T5 vertebrae and inserts into the inferomedial part of the scapula. 7 Since it is a thin muscle situated between the middle trapezius above and the pleura and major neurovascular structures below, blind injections in this region carry a relatively high risk of complications. This risk has led to more frequent use of superficial injections of the trigger points to avoid the complications of the blind (not ultrasound [US]-guided) technique. [8] [9] [10] Currently, US is the preferred imaging modality for guiding invasive interventions in the musculoskeletal system 11 to avoid the risk of iatrogenic complications due to blind injections. 10 Deep injections in the lumbar region have been reported to be more effective in myofascial pain syndrome treatment.
12, 13 We could not find a study in the literature concerning the comparison of deep and superficial injections in the middle back region. This study was designed to investigate the effect of US-guided injections of the rhomboid major (deep) and trapezius (superficial) muscles on pain, disability, and quality of life in patients with myofascial pain syndrome to avoid interventional complications.
Materials and Methods
In this prospective randomized controlled double-blind study, 80 patients with a diagnosis of myofascial pain syndrome based on the diagnostic criteria of Simons et al 1 
Patients
The inclusion criteria were as follows: (1) to be between the ages of 18 and 60 years, (2) to have midback pain for greater than 3 months, and (3) to have at least 1 active trigger point. The exclusion criteria were as follows: (1) cervical radiculopathy, (2) fibromyalgia, (3) shoulder joint disease, (4) peripheral or central nervous system disease, (5) polyneuropathy, (6) inflammatory rheumatic disease, (7) malignancy, (8) anticoagulant therapy, (9) history of physical therapy or injection for myofascial pain syndrome within the past 6 months, and (10) use of analgesics in the previous 48 hours before evaluation.
Sixty-five patients who were eligible for the study were given detailed information about the study, and an informed consent form was signed. Forms detailing the patients' demographic characteristics and pretreatment (week 0) measurements were completed. Informed consent was obtained from all participants included in the study.
Randomization
Patients included in the study were divided into 2 groups by a random-number table. In group 1 (n 5 33) US-guided rhomboid major muscle (deep) injection was performed, and in group 2 (n 5 32), US-guided trapezius muscle (superficial) injection was performed ( Figure 1 ). The patients were not informed about which muscle was injected.
Interventions
The patients were seated in a neutral position. The active myofascial trigger point that was the most painful was palpated and marked with a pen. After cleansing of the skin with a suitable antiseptic agent, the mid trapezius and rhomboid major muscles were imaged with the 12-18-MHz linear US transducer (MyLab 30; Esaote SpA, Genoa, Italy) placed in sagittal position over the region with the active trigger point (Figure 2 ). Three-milliliter 0.25% bupivacaine injections were applied into either the mid trapezius or rhomboid major muscle by the in-plane technique with a 5-cm, 22-gauge, US-visible needle from only a single point (Figure 3 ). Injections were performed by an expert physiatrist trained in musculoskeletal US.
The same researcher, who was blinded to the type of treatment, completed posttreatment second-and fourth-week (W4) evaluations and recorded the data.
Evaluation Parameters Visual Analog Scale
The visual analog scale (VAS) is a widely used scale developed by Price et al 14 to assess the severity of pain felt by a patient. The patient rated pain on a scale of 0 to 10, with 0 representing no pain and 10 representing the worst pain imaginable.
Pressure Pain Threshold (Algometry/Dolorimetry) The Pain Pressure Threshold is an instrument that objectively measures the pain threshold and pain tolerance. The algometer used in this study (Baseline Dolorimeters, New York, NY) consists of a metal piston with a round rubber disk of about 1 cm in diameter attached to a dial that measures pressures in kilograms and pounds. The user can apply the desired pressure by holding the handset. The initial pressure at which the patient felt pain was recorded in kilograms. The procedure was repeated 3 times at intervals of 60 seconds to evaluate the mean kilogram pressure pain threshold. 15, 16 Neck Pain and Disability Scale The Neck Pain and Disability Scale consists of 20 items. Each item is scored on a 10-cm VAS and scored between 0 and 5 points. The reliability and validity of its Turkish version were previously shown by Biçer et al. 17 The items assess the severity of pain and its relationship with the effects of occupational, recreational, social, and daily life activities and emotional factors. Thus, the scale measures the effects of neck pain on functionality, quality of life, and disability. The total score is the sum of the points for each item and ranges between 0 and 100. Higher scores indicate greater severity. 17 
Short Form 12
Twelve different items were taken from the 8 different headings of Short Form 36, and the shorter Short Form 12 was created. 18 Short Form 12 has physical and mental component scales for which regression analyses have been performed in the general public. The physical and mental health sum scales are computed by using the scores for 12 questions and range from 0 to 100, where 0 indicates the lowest level of health measured by the scales and 100 indicates the highest level of health. 19 No analgesics were given to the patients throughout the study.
Statistical Analysis
An analysis of the collected data was performed with the SPSS version 22.0 statistical program (IBM Corporation, Armonk, NY). When the study data were evaluated, the Pearson v 2 and Yates v 2 tests were used for comparison of the categorical variables in addition to descriptive statistical methods (frequency, percentage, mean, and standard deviation). The distribution of the data was tested by the Shapiro-Wilk test, and the data were distributed normally. The independent-samples t test (t test for independent groups) was used for between-group comparisons, and the paired-sample t test was used for intragroup comparisons. P < .05 was accepted as significant.
Results
One patient from group 1 and 3 patients from group 2 abandoned the study for private reasons. No patient was left out of the study because of any side effect from the treatment. The study was completed with a total of 61 patients (group 1, n 5 32; and group 2, n 5 29; Figure 1 ).
The distributions of the patient's ages, body mass indices, and symptom durations are presented in Table 1 . The pretreatment evaluation parameters in both groups are presented in Table 2 . There was no statistically significant difference between the groups for demographic characteristics and pretreatment evaluation parameters (P > .05).
In both groups, statistically significant improvements were observed for all parameters at both the second and fourth posttreatment weeks compared to pretreatment values (P < .05; Table 2 ). The VAS score before treatment in groups 1 and 2 decreased progressively at weeks 2 and 4. The decrease in the VAS score at both weeks 2 and 4 was statistically significant in favor of group 1 (Tables 2 and 3) . A comparison of the groups showed statistical significantly superior results in group 1 for all parameters at week 2 (P < .05) and for all parameters but the Physical Component Scale at week 4 (P < .05; Table 3 ). Data are presented as mean 6 SD where applicable. The c 2 test and the independent-samples t test were used for intergroup comparisons. NA indicates not applicable.
Discussion
The results of our study showed that significantly better improvement in pain, disability, and quality of life was obtained with US-guided injection of the rhomboid major muscle compared to injection of the trapezius muscle in patients with myofascial pain syndrome at both 2 and 4 weeks after treatment.
Trigger points in myofascial pain syndrome are believed to develop as a result of sensitization by various factors of nociceptors, such as polymodal-type receptors located in the skin, fascia, and muscle. Since these receptors respond to chemical, thermal, and mechanical stimuli, which can create an analgesic effect, injection of the trigger points may provide stronger analgesia than other methods by causing increased activity of the polymodal-type receptors. 12, 20, 21 The mechanism of action has been explained as hyperstimulation analgesia via the descending pain inhibition system. The gate control theory of Melzack 22 describes modulation of the sensory stimulus through the inhibitor mechanisms in the central nervous system. Needle stimulus of the myofascial trigger point may send strong signals to the dorsal horn cells and thus disrupt the pathologic circuitry of the trigger point. 23, 24 Although the effect of superficial needling is limited to the cutaneous polymodal-type receptors, deep injections can also provide activation of the receptors located in the muscle and fascia. 13, 25 Ceccherelli et al 13 suggested that muscle afferents were more crucial for conveying analgesic signals compared to the cutaneous afferents. The technique of US-guided injection of the rhomboid major muscle used in our study may have resulted in stronger analgesia by allowing more effective stimulation and activation of the polymodal-type receptors in the pathway of the needle all through the skin, subcutaneous tissue, trapezius muscle, fascia, and rhomboid muscle. In addition, in a study comparing the efficacy of dry needling and lidocaine injections in myofascial pain syndrome, postinjection pain was reported to be more severe with dry needling. 16 For this reason we performed injections with a local anesthetic.
Few studies have investigated the comparative effect of injections at varying depths. 12, 13, 26 N€ aslund et al 26 investigated the effects of deep and minimal superficial injections on pain and function in 58 patients with idiopathic anterior knee pain who were treated twice a week in a total of 15 sessions. In that study, VAS scores in the deep injection group decreased from 25 to 10, whereas in the superficial (placebo) injection group, the VAS scores declined from 30 to 10, and they did not find any statistically significant difference between the groups. In a doubleblind randomized study of lumbar myofascial pain syndrome, superficial injection within 2 mm of the skin and deep injection of the muscle were compared. According to the evaluation results obtained from the McGill Pain Questionnaire, there was no difference immediately, but deep injection was found to result in significantly superior pain scores compared to superficial injection. 13 Deep injection was superior in pain relief to standard acupuncture and superficial injection in another study performed on 27 patients older than 65 years with chronic back pain. 12 In a review, Kalichman and Vulfsons 27 suggested that deep injections were more effective; however, they recommended superficial injections in hazardous regions, including the lungs and major blood vessels. The results of our study showed that deep injections (rhomboid major) were more effective than superficial injections (trapezius), corroborating the results of the above studies.
Although US guidance is currently used frequently for invasive interventions such as injections into musculoskeletal structures, 11 we could find only 1 study about US-guided injections for myofascial pain syndrome treatment. In that study, Cho et al 28 compared the effect of pulsed radiofrequency and local anesthetic injection into the interfascial space between the rhomboid major and trapezius muscles on pain and quality of life, and they found a statistically significant improvement in both groups.
Comparative effects of dry needling and wet injection of a local anesthetic in myofascial pain syndrome have been assessed in several studies. 5, 29 In a metaanalysis of 20 randomized controlled trials, Liu et al 29 reported that dry needling could be recommended for neck and shoulder pain development due to myofascial trigger points for short and middle terms, but wet injection was more effective during the middle term of 9 to 28 days. G€ uzel et al, 30 on the other hand, observed that the therapeutic effect of local anesthetic injection started faster than that of dry needling and suggested that priority should be given to the former method for myofascial pain syndrome treatment. We preferred wet injection with a local anesthetic in our study and obtained a substantial therapeutic effect in the early period, corroborating the observations of the latter study.
On the other hand, in trigger point injections, side effect related to vasovagal symptoms, such as syncope and hypotension, 31 may be seen, as well as complications due to the injection technique, such as pneumothorax, air embolism, intrathecal injections, spinal cord injury, peripheral nerve injuries, and muscle injuries. 32 We think that complications due to injection techniques can be prevented by using US. However, US has not shown any benefit in preventing vasovagal symptoms.
In conclusion, the results of our study showed that US-guided deep injection of the rhomboid major muscle was more effective than superficial injection of the trapezius muscle for the parameters of pain, disability, and quality of life in patients with myofascial pain syndrome. The lack of a placebo intervention group, small sample size, and relatively short follow-up period were the obvious limitations of our study. We believe that further studies with a placebo-controlled design and a longer follow-up period in a larger patient population are required for better understanding of the topic.
